Hyperlipoproteinemia Type II

It is a familial disorder with a genetic basis. The grounding supports heterozygous forms of the condition and broader inherited lipid-disorder genetics, but does not specify individual causal genes or variants.

The disorder involves abnormal elevation of LDL cholesterol in blood, with some cases also showing increased VLDL-related cholesterol. The literature grounding links this to inherited defects in lipoprotein metabolism and to genetic pathways that drive lipoprotein disorder biology.

A family history or inherited predisposition is supported by the grounding, including heterozygous familial disease. The literature also indicates that affected individuals may be underdiagnosed, but it does not provide additional risk factors.

Management is described at the level of lipid-lowering therapy and screening for familial hypercholesterolemia. The grounding also supports genetic testing as part of inherited cardiovascular disease care, and notes emerging gene-based therapies such as RNA-based, gene addition, and gene-editing approaches for lipoprotein disorders.